Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/31/2025

Diagnostic Challenges in Substance/Medication-Induced Psychotic Disorder

DSM-5-TR Weaknesses

  • The American Psychiatric Association's DSM-5-TR lacks specific symptom and duration requirements for substance-induced mental disorders, creating a flexible approach that is problematic 1
  • The DSM-5-TR only requires that the disorder "resembles" the full criteria for the relevant disorder, rather than meeting the same duration and symptom criteria as the corresponding primary diagnosis 1
  • The removal of the requirement that symptoms exceed expected intoxication or withdrawal symptoms creates diagnostic uncertainty about when psychotic symptoms represent a true substance-induced disorder versus expected pharmacological effects 1
  • The absence of minimum duration requirements makes it difficult to distinguish transient intoxication-related symptoms from clinically significant substance-induced psychotic disorders 1
  • The lack of specific timeframes for symptom persistence after cessation of acute withdrawal or intoxication reduces diagnostic precision 1, 2

ICD-11 Strengths

  • ICD-11 introduced dimensional assessments for psychotic disorders while maintaining categorical structure, allowing for more nuanced symptom profiles that inform treatment in specialized settings and research 3
  • The Clinical Descriptions and Diagnostic Guidelines (CDDG) provide detailed descriptions regarding core symptoms, differential diagnosis, and boundaries with normal functioning 3
  • ICD-11 underwent the largest participative revision in classification history, with field studies demonstrating higher reliability and clinical utility compared to ICD-10 3, 4
  • ICD-11 maintains a stepwise diagnostic approach that combines categorical classification for clinical utility with optional dimensional assessments for specialized contexts 3
  • Reinstate the 4-week persistence criterion after cessation of acute withdrawal or intoxication as a minimum requirement for diagnosis, as this was supported by DSM-IV research demonstrating reliable and valid diagnosis 1
  • Require documentation of symptom onset timing relative to substance/medication initiation and dose changes 1, 2
  • Extend ICD-11's dimensional assessment approach to substance/medication-induced psychotic disorders, allowing clinicians to rate symptom domains on at least a 3-point scale 3
  • Create formal harmonization working groups between DSM and ICD systems to align diagnostic thresholds and improve concordance for substance-induced disorders 4
  • Develop shared biomarker standards and neurobiological assessment tools that could supplement self-report criteria and improve diagnostic objectivity 1, 4

ICD‑11 Clinical Utility and Reliability for Opioid‑Related Disorders

Clinician Perception of Usability

  • In a field study involving 928 clinicians, 82 %–84 % rated the International Classification of Diseases, 11th Revision (ICD‑11) as “quite” or “extremely” easy to use, accurate, clear, and understandable for diagnosing opioid‑related disorders. Evidence level: moderate (large‑scale clinician survey) 5

Diagnostic Accuracy and Efficiency

  • Compared with ICD‑10, ICD‑11 demonstrated higher diagnostic accuracy, shorter time to reach a diagnosis, and greater perceived clinical utility across multiple international field studies evaluating opioid‑related disorder assessment. Evidence level: moderate (multicenter field trials) 5

Inter‑rater Reliability Across Disorder Types

  • In reliability testing, ICD‑11 showed high inter‑rater agreement for psychotic disorders but only moderate agreement for mood and stress‑related disorders, indicating variable performance of the classification when applied to opioid‑induced psychiatric conditions. Evidence level: moderate (reliability study) 5

REFERENCES

2

Integrated Treatment Approach for Comorbid Alcohol Use Disorder and Major Depressive Disorder [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

4

Evolution of Substance Use Disorder Diagnosis [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026